To test this hypothesis and evaluate the anti-tumor effects of combining chemotherapy and a SERD in wild-type (WT) and mutant ER, we conducted a comprehensive analysis of the combination of chemotherapy and fulvestrant in in vitro and in vivo pre-clinical models. The gene discussed is ESR1; the disease is neoplasm.